Innate pharma launches a capital increase to raise up to 15% of current capital

This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only.

Innate pharma launches a capital increase to raise up to 15% of current capital

• The capital increase is directed to specialist institutional investors

Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases (the “Company”), has launched today a capital increase directed to institutional investors specializing in pharma and biotech, with the objective of raising up to 15% of the current share capital of the Company.
This capital increase announced today will give the Company the means to finance its portfolio of proprietary candidates through 2017.

The capital increase will be carried out without shareholders’ preferential subscription rights. As per Article L. 225-138 of the French Commercial Code and the sixteenth resolution of the Shareholders General Meeting of the Company dated March 27, 2014, it will be reserved to the categories defined in the above-mentioned resolution, i.e.: (i) to industrial or commercial companies in the pharmaceutical / biotechnology sector, and (ii) to French or foreign investment funds investing in the pharmaceutical / biotech sector.

Application will be made to list the new shares on Euronext Paris. A listing prospectus will be submitted to the French financial markets authority (Autorité des Marchés Financiers).